News

LiveDrop-Bio unveils ModaFlow 4L5C: Revolutionizing biotherapeutic discovery with picoscale droplet technology

Press release
Liège, Belgium – January 8, 2025 – LiveDrop is excited to announce the commercial launch of the new ModaFlow 4L5C, a cutting-edge picoscale droplet bioassay platform designed to advance precision cell and prokaryote screening workflows, functional bioassays in drug discovery, and the exploration of single or multi-cell secretome.

This groundbreaking instrument combines droplet microfluidics with unmatched precision and throughput, enabling researchers to screen extensive collections of cells far faster and more efficiently than traditional 96 or 384-well formats.

Transforming Months into Days

By processing and analyzing thousands of assays per second with high standardization and statistical relevance, the new ModaFlow 4L5C empowers laboratories to bring new treatments to market faster and more cost-effectively.

Resolving Bottlenecks into Efficient Droplet-Based Workflows

LiveDrop’s expertise in biology and microfluidics ensures seamless integration of the most promising droplet bioassays into routine workflows, enabling researchers to accelerate critical workflows. This hands-on support uniquely accelerates and de-risks the adoption of droplet innovative technology, allowing teams to transition smoothly while maximizing efficiency and confidence.

Unique Features Set the ModaFlow 4L5C Apart in Its Market Segment

  • Four lasers and five detection channels, enabling unparalleled flexibility and multiplexing capabilities for complex bioassays.
  • Patented zero dead-volume microfluidic connectors, allowing researchers to work with minimal starting material without waste and instant priming—an essential feature for resource-sensitive workflows.
  • Advanced fluorescence gating capabilities and user-friendly design, helping streamline precision processes and accelerate results in high-throughput screening.

Impact on the Industry

Beyond biopharmaceutical applications, LiveDrop’s picoscale droplet technology is also making strides in microbiology, multi-omics, and 3D cell culture models, such as spheroid production for drug testing.

Quotation

“Droplet microfluidics integrated with LiveDrop’s advanced bioassays is revolutionizing immunology research. These tools enable high-throughput B-cell screening, monoclonal antibody discovery, and single-cell antibody response studies with unmatched precision—a game-changer technology to support innovation in Life Sciences.

By rapidly screening plasma cells and Fc receptor interactions, LiveDrop drives breakthroughs in autoimmune and allergy therapies, transforming our understanding of human immunity.”

Dr. Adrien Boes, CER Groupe, Belgium

Limited Time Opportunity for Early 2025!

Kick off the new year with an exclusive proof-of-concept (POC) opportunity from LiveDrop to showcase the capabilities of ModaFlow. Researchers are invited to bring their bioassay challenges, and LiveDrop’s team of experts will assist in transforming them into droplet-based formats.

This offer is available through February 28th, 2025. Secure your spot now, as availability is limited!

About LiveDrop SA

Founded in 2022 as a spin-off from the University of Liège, LiveDrop SA is led by CEO and CTO Dr. Stéphanie van Loo, a biomedical engineer and biotechnologist. LiveDrop’s mission is to provide both industrial and academic laboratories with the revolutionary robustness of droplet biology. The company aims to simplify this groundbreaking technology and set new industry standards in cell biology, molecular biology, and microbiology.

Contact Information

For further inquiries, please contact:

François Dohet, VP Business Development & Sales
Phone: +32 496 23 20 15
Email: [email protected]

LiveDrop SA
GIGA – B34, Avenue de l’Hôpital 11, 4000 Liège, Belgium
Phone: +32 4 378 68 16
Email: [email protected]
Website: www.livedrop-bio.com

High-resolution images are available upon request.